Genmab A/S appears to be attracting mixed market sentiments, along with analyst insights. Forecasts point to Genmab as one of the most profitable growth stocks in healthcare, with numerous share buy-back transactions indicating significant board confidence. It also seems to be popular among value investors. Share price cuts, however, have been noted by H.C. Wainwright & RBC Capital, causing moderate market concern. Genmab faced significant challenges in 2024 but reported strong Q1 2025 financial results and robust DARZALEX sales, offsetting previous losses to some extent. Some institutional owners are concerned about recent market dips and may initiate dramatic action. J&J's decision to exit the HexaBody-CD38 collaboration is significant news that has implications for the HexaBody platform. Accusations of exploiting trade secrets by AbbVie and licensing setbacks may negatively affect the firm. Despite these challenges, Genmab's share buy-back program, coupled with various strategic initiatives, suggests resilience amidst difficulties. However, concerns regarding post-Darzalex challenges and potential impacts on 2025 earnings are prevalent. Barclays maintains its buy rating on Genmab, while Morgan Stanley highlights uncertainties.
Genmab Stocks News Analytics from Tue, 20 Aug 2024 07:00:00 GMT to Fri, 16 May 2025 15:00:00 GMT -
Rating -1
- Innovation 3
- Information 5
- Rumor -5
